Pellegrino, Raffaello http://orcid.org/0000-0001-5874-0376
Paganelli, Roberto http://orcid.org/0000-0003-3467-9317
Di Iorio, Angelo http://orcid.org/0000-0003-2899-146X
Bandinelli, Stefania http://orcid.org/0000-0002-6491-0850
Moretti, Antimo http://orcid.org/0000-0002-4598-2891
Iolascon, Giovanni http://orcid.org/0000-0002-0976-925X
Sparvieri, Eleonora http://orcid.org/0000-0003-4338-2558
Tarantino, Domiziano http://orcid.org/0000-0003-1570-9568
Ferrucci, Luigi http://orcid.org/0000-0002-6273-1613
Article History
Received: 23 June 2023
Accepted: 26 July 2023
First Online: 2 August 2023
Declarations
:
: The InCHIANTI study baseline was approved by the Ethical Committee at INRCA, Ancona (protocol 14/CE, 28 February 2000) as the FU1 (protocol 45/01, 16 January 2001). InCHIANTI study FU2 and FU3 were approved by the local Ethical Committee at Azienda Sanitaria Firenze (protocol no. 5/04, 12 May 2004). The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of INRCA di Ancona (Italy). Clinical Trial Registration NCT01331512.
: Written informed consent was obtained from the patients to participate at the study.
: The authors declare no competing interests.